Groupement Hospitalier Edouard Herriot

Lyon 69437

0 studies enrolling now · 2 studies all time

What they study most

Advanced Cholangiocarcinoma, Cytomegalovirus (CMV), FGFR2 Gene Mutation

Studies at this site

• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
• Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir — Completed